CN107619869B - Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application - Google Patents
Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application Download PDFInfo
- Publication number
- CN107619869B CN107619869B CN201711056928.1A CN201711056928A CN107619869B CN 107619869 B CN107619869 B CN 107619869B CN 201711056928 A CN201711056928 A CN 201711056928A CN 107619869 B CN107619869 B CN 107619869B
- Authority
- CN
- China
- Prior art keywords
- glioma
- circ16
- diagnosis
- prognosis
- brain tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 47
- 206010018338 Glioma Diseases 0.000 title claims abstract description 47
- 238000003745 diagnosis Methods 0.000 title claims abstract description 22
- 238000004393 prognosis Methods 0.000 title claims abstract description 17
- 239000003550 marker Substances 0.000 title abstract description 10
- 210000005013 brain tissue Anatomy 0.000 claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 238000010839 reverse transcription Methods 0.000 claims description 10
- 238000003753 real-time PCR Methods 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 abstract description 13
- 108091028075 Circular RNA Proteins 0.000 abstract description 8
- 230000004083 survival effect Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 5
- 230000002980 postoperative effect Effects 0.000 abstract description 2
- 238000013211 curve analysis Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 201000007983 brain glioma Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a glioma diagnosis and prognosis marker circ16:85633914|85634132 and application, namely a reagent for detecting a brain tissue source ring RNAcirc16:85633914|85634132 is used for preparing a diagnosis and prognosis preparation for a glioma patient. The research proves that the expression level of the circular RNA circ16:85633914|85634132 in the brain tissue of a glioma patient is obviously reduced compared with that of the normal brain tissue, and ROC curve analysis shows that the circular RNA circ16:85633914|85634132 has higher diagnosis performance on glioma. Meanwhile, the circ16:85633914|85634132 has higher postoperative survival rate. By detecting the expression level of the circular RNA circ16:85633914|85634132 in the glioma tissues of patients with glioma, the diagnosis analysis and prognosis judgment of high-risk glioma people can be carried out.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to a circRNA marker for glioma diagnosis and prognosis analysis, application of a reagent for detecting the marker in preparation of a glioma diagnosis and prognosis preparation, and a kit.
Background
Brain glioma is the most frequent brain tumor disease of adults, and accounts for 40.49 percent of intracranial tumors. From the time of diagnosis, the average life span of brain glioma patients does not exceed five years. In order to diagnose glioma, a malignant disease with a very high genetic material correlation, the pathogenesis of glioma must be explored at the molecular biological level from the aspect of genetic information expression. At present, the diagnosis and treatment methods of glioma are in the continuous improvement stage, but the survival rate of glioma patients is not obviously improved. Glioma diagnosis is still in an empirical stage based on clinical, pathological and imaging information, and once diagnosed, most of them are in middle and advanced stages, and the survival rate after surgery is not optimistic. Therefore, the search of glioma prognostic markers for carrying out prognostic analysis on patients, the improvement of the postoperative life quality of glioma patients, the corresponding selection of reasonable subsequent treatment schemes and the improvement of survival rate are research tasks to be solved urgently in the field of neuroscience.
The circular RNA is a kind of endogenous non-coding RNA molecules which are widely and diversely present in mammalian cells and have the function of regulating gene expression, has a covalently closed circular structure, is widely present in various cells, and is also a latest research hotspot of an RNA family following microRNA (miRNA). In recent years, with the widespread use of deep sequencing technologies and the rapid development of biophysical and informatics technologies, it has been found that human transcripts of many exons can be non-linearly reverse spliced or rearranged through genes to form circular RNAs, and that they account for a significant proportion of all spliced transcripts. At present, the circular RNA plays an increasingly important role in the aspect of tumor markers due to the characteristics of richness, stability, high conservation, space-time specificity and the like. Meanwhile, precise medicine and glioma molecular typing are gradually the current focus, and compared with the traditional morphological typing, the molecular typing provides possibility for revealing cytological and genetic essence of glioma occurrence and development, so that the circular RNA is expected to play a greater role in the aspect, becomes a novel glioma molecular typing marker, and provides a new direction for targeted therapy of glioma.
Disclosure of Invention
The first object of the present invention is: provides a circRNA marker of brain tissue origin for glioma diagnosis and prognostic analysis.
The main contents comprise: a circRNA marker circ16:85633914|85634132 for glioma diagnosis and prognosis analysis has a sequence shown in SEQ NO 1.
The second purpose of the invention is to provide the application of the reagent for detecting the expression quantity of the circRNA marker in brain tissues in preparing glioma diagnosis and prognosis preparations.
It is a third object of the present invention to provide a glioma diagnosis and prognosis kit capable of determining the content of circ16:85633914|85634132 in brain tissue.
The glioma diagnosis and prognosis analysis kit contains a PCR primer for detecting the content of circ16:85633914| 85634132. Preferred primers have the sequences shown in SEQ NO 2 and 3.
The glioma diagnosis and prognosis analysis kit contains a PCR primer for detecting circ16:85633914|85634132 and all reagents for extracting RNA from brain tissues and carrying out reverse transcription and fluorescence quantitative PCR.
The preparation comprises (1) reagents required for extracting tissue RNA, namely Trizol reagent, trichloromethane, isopropanol, 75% ethanol and enzyme-free water, (2) reagents required for reverse transcription, namely Random Primer, enzyme-free water, 5 × reverse transcription buffer solution, triphosphate base deoxynucleotide, RNase inhibitor and MMLV reverse transcriptase which are all purchased from Thermo company, and (3) reagents required for fluorescence quantitative PCR, namely Primer pairs shown in SEQ NO:2 and 3, Primer pairs of internal reference GAPDH, SYBR dye and enzyme-free water.
The invention has the beneficial effects that: the difference expression of the circular RNA circ16:85633914|85634132 in glioma brain tissue and normal tissue is found for the first time, and the glioma has higher diagnosis and prognosis analysis values; by applying the cyclic RNA in glioma diagnosis and prognosis analysis, the diagnosis and prognosis of glioma are more convenient and accurate, a foundation is laid for a clinician to quickly and accurately master the state of illness of a patient, the clinical treatment effect is improved, and help is provided for finding a novel micromolecule drug target with potential treatment value.
Drawings
FIG. 1 shows the difference between circ16:85633914|85634132 expression in glioma tissues and normal brain tissues analyzed by real-time fluorescent quantitative PCR;
FIG. 2 shows the specificity and sensitivity of Roc analysis of glioma-derived circ16:85633914|85634132 in early diagnosis of glioma.
FIG. 3 is a graph of survival analysis of the correlation between glioma-derived circs 16:85633914|85634132 and glioma patient survival.
Detailed Description
The following is intended to further illustrate the invention in connection with the embodiments, and not to limit the invention.
First, research object
Tumor tissues of 30 patients with glioma and 15 normal brain tissues were provided by tumor hospitals in Hunan province.
1. Extraction of RNA from glioma/Normal tissue
0.1g of each of the tumor and normal brain tissues is taken, the obtained mixture is placed into a mortar (the mortar needs to be wrapped by tin foil paper in advance and baked in an oven at a high temperature of 180 ℃ for 6-8 hours) after being washed by a proper amount of normal saline, a proper amount of liquid nitrogen is added to grind the tissues into powder, 0.6ml of Trizol (MRC company) is added to continue grinding for a plurality of minutes, 0.4ml of Trizol is added again, the mixture in the mortar is transferred to a 1.5ml enzyme-free Tube, and the mixture is cracked for 15 minutes on ice. After the cleavage was completed, the Tube was transferred to a 1.5ml enzyme-free Tube, centrifuged at 12000rpm at 4 ℃ for 10min, and the supernatant was transferred to a new Tube. Adding 200 μ l chloroform into Tube, shaking by hand for 15-30s, standing on ice for 5min, and centrifuging at 4 deg.C and 12000rpm for 15 min; carefully taking the upper water phase into a new tube, adding 0.5ml of precooled isopropanol, uniformly mixing, standing on ice for more than 20min, and centrifuging at 4 ℃ and 12000rpm for 10 min; discarding supernatant, adding 1ml ethanol diluted with 75% DEPC water, mixing, centrifuging at 4 deg.C and 7500rpm for 5min, discarding supernatant as much as possible, drying at room temperature for 5-10min, adding 20 μ l enzyme-free water to dissolve RNA, and storing at-80 deg.C.
Preparation of cDNA
Reverse transcription was performed according to the instructions of the reverse transcription kit (Thermo Co.). The total volume of the reaction was 20. mu.l.
| Composition (I) | Dosage/tube |
| Random reverse transcription primer (1. mu.M) | 1μl |
| RNA samples | 1μg |
| Enzyme-free water | To 12μl |
Reverse transcription first step conditions: 5 minutes at 65 DEG C
Reverse transcription second step procedure: 5 minutes at 25 ℃, 60 minutes at 42 ℃ and 5 minutes at 70 ℃.
3. Real-time fluorescent quantitative PCR
The real-time quantitative PCR is carried out by adopting specific primers (sequences are shown in SEQ NO:2 and 3) synthesized by Hanhengzheng biotechnology (Shanghai) Limited company: firstly, the reverse transcription product is diluted by 10 times and mixed evenly. The 20 μ L reaction was as follows:
| composition (I) | Dosage/tube |
| SYBR Premix Ex Taq | 10μl |
| Specific primers (both upstream and downstream 10. mu.M) | 0.5μl |
| cDNA product (after dilution) | 5μl |
| Enzyme-free water | To 20μl |
Real-time fluorescent quantitative PCR reaction program: 95 ℃ for 3 minutes, 40 cycles, 95 ℃ for 10 seconds, 60 ℃ for 30 seconds.
(6) And (3) data analysis: by using 2-ΔΔCTExpression fold of circ16:85633914|85634132 in brain tissue of glioma patients relative to normal brain tissue, wherein △ CT ═ CTSample(s)–CTInternal reference，ΔΔCT＝ΔCTGlioma–ΔCTIs normal. The experimental data were analyzed by a relatively quantitative method using GAPDH as reference gene (primer sequences shown in SEQ NO: 4 and 5), Δ CTIs normalIs the average of Δ CT of normal brain tissue. Data were analyzed using software GraphPad Prism and SPSS 17.0.
Third, research results
1. A significant reduction in circ16:85633914|85634132 in glioma tissue compared to normal tissue
(P ═ 0.003, the specific results are shown in fig. 1). The ROC curve shows that it has high diagnostic value for glioma (AUC 0.858, P0.001, sensitivity 90%, specificity 80.8%), and the detailed results are shown in fig. 2.
2. Through the follow-up statistical data of 30 glioma patients adopted in the experiment, 10 patients are not connected due to the halt of a mobile phone or the change of numbers or other reasons during follow-up, and the number of the glioma patients or family members which can be finally connected is 20, and the 20 patients or family members receive the follow-up analysis. We asked the time of first onset, treatment, recurrence and death of these patients or families in detail, with follow-up period of 1-42 months. In selected glioma patients, the expression value of fluorescent quantitative PCR analysis is selected as a reference standard, the obtained results are high-expressed in a circ16:85633914|85634132 which is higher than the median after descending order arrangement, and the other results are low-expressed in a circ16:85633914|85634132 which are 10 cases in total. Through Kaplan-Meier survival analysis, the survival time of the circ16:85633914|85634132 high-expression patient is longer than that of the circ16:85633914|85634132 low-expression patient, and the survival time is better. The difference is statistically significant (P ═ 0.046). The detailed results are shown in FIG. 3.
Sequence listing
<110> Hunan ya Hospital of Zhongnan university
<120> glioma diagnosis and prognosis marker circ16:85633914|85634132 and application
<160>5
<170>SIPOSequenceListing 1.0
<210>1
<211>219
<212>RNA
<213> Intelligent (Homo sapiens)
<400>1
gcaugagcca ugagcccaag uccccuucgc uagggaugcu uuccaccgcg accaggacca 60
ccgccaccgu caacccccuc acccccucgc cgcucaaugg cgcccuggug cccagcggca 120
gccccgccac cagcagcgcg cugucggccc aggccgcgcc auccuccagc uuugccgccg 180
cgcugcgcaa gcucgccaaa caggcggagg agcccagag 219
<210>2
<211>18
<212>DNA
<213> Unknown (Unknown)
<400>2
ccatcctcca gctttgcc 18
<210>3
<211>17
<212>DNA
<213> Unknown (Unknown)
<400>3
gtcgcggtgg aaagcat 17
<210>4
<211>19
<212>DNA
<213> Unknown (Unknown)
<400>4
atcatcagca atgcctcct 19
<210>5
<211>18
<212>DNA
<213> Unknown (Unknown)
<400>5
catcacgcca cagtttcc 18
Claims (4)
1. The application of the reagent for detecting the expression quantity of circ16:85633914|85634132 in brain tissues in preparing a glioma diagnosis and prognosis preparation, wherein the sequence of the circ16:85633914|85634132 is shown as SEQ NO 1.
2. The use of claim 1, wherein the reagent for detecting the expression level of circ16:85633914|85634132 in brain tissue comprises PCR primers for detecting the content of circ16:85633914| 85634132.
3. The use of claim 2, wherein the primer has the sequence shown in SEQ ID Nos. 2 and 3.
4. The use of claim 2 or 3, wherein the reagent for detecting the expression level of circ16:85633914|85634132 in brain tissue comprises all reagents for extracting RNA from brain tissue and performing reverse transcription and fluorescence quantitative PCR, in addition to the primer of circ16:85633914| 85634132.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711056928.1A CN107619869B (en) | 2017-10-27 | 2017-10-27 | Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711056928.1A CN107619869B (en) | 2017-10-27 | 2017-10-27 | Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107619869A CN107619869A (en) | 2018-01-23 |
| CN107619869B true CN107619869B (en) | 2020-06-30 |
Family
ID=61093329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711056928.1A Expired - Fee Related CN107619869B (en) | 2017-10-27 | 2017-10-27 | Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107619869B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109161593B (en) * | 2018-02-14 | 2020-03-17 | 易瑞达(福建)生物技术有限公司 | Application of circular RNA and microRNA in colorectal cancer screening and diagnosis |
| CN114277031A (en) * | 2022-01-25 | 2022-04-05 | 上海纽仁生物医药科技有限公司 | hsa _ circ _0006420 circular RNA and application thereof in glioma diagnosis and prognosis evaluation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012089753A2 (en) * | 2010-12-30 | 2012-07-05 | Febit Holding Gmbh | Complex sets of mirnas as non-invasive biomarkers for glioblastoma |
| CN103966337A (en) * | 2014-05-26 | 2014-08-06 | 中南大学 | Application method of serum Exosomes-derived long non-coding RNA PRKAG2-AS1 |
-
2017
- 2017-10-27 CN CN201711056928.1A patent/CN107619869B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012089753A2 (en) * | 2010-12-30 | 2012-07-05 | Febit Holding Gmbh | Complex sets of mirnas as non-invasive biomarkers for glioblastoma |
| CN103966337A (en) * | 2014-05-26 | 2014-08-06 | 中南大学 | Application method of serum Exosomes-derived long non-coding RNA PRKAG2-AS1 |
Non-Patent Citations (3)
| Title |
|---|
| Circular RNAs are abundant, conserved, and associated with ALU repeats;Jeck WR 等;《RNA》;20121218;第19卷(第2期);第141-157页 * |
| Jeck WR 等.Circular RNAs are abundant, conserved, and associated with ALU repeats.《RNA》.2012,第19卷(第2期), * |
| Prediction of central nervous system embryonal tumour outcome based on gene expression;Scott L. Pomeroy 等;《NATURE》;20120124;第415卷;第436-442页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107619869A (en) | 2018-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109852688B (en) | Diagnostic primer and kit for type 2 diabetes mellitus and application of non-coding RNA molecular marker | |
| CN107674916B (en) | Application of circular RNA in colorectal cancer biomarker | |
| WO2016186987A1 (en) | Biomarker micrornas and method for determining tumor burden | |
| CN107779504B (en) | MicroRNA molecular marker for colorectal cancer and application thereof | |
| Nie et al. | Circulating miR-125b as a biomarker of Ewing’s sarcoma in Chinese children | |
| CN107619869B (en) | Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application | |
| CN107937532B (en) | Glioma diagnosis marker hsa _ circ _0021827 and application | |
| CN108950003B (en) | miRNA marker for diagnosing breast cancer and application of miRNA thereof | |
| CN107557472B (en) | Glioma diagnosis marker circ9:135881633|135883078 and application | |
| CN107475441B (en) | Biomarker for predicting responsiveness of breast cancer patient to AT regimen neoadjuvant chemotherapy | |
| CN108624693A (en) | Applications of the miR-577 in preparing diagnosis of nephropathy marker | |
| EP2657354A1 (en) | Microrna expression signature in peripheral blood of patients affected by hepatocarcinoma or hepatic cirrhosis and uses thereof | |
| CN107674915B (en) | Application of circular RNA in colorectal cancer biomarker | |
| CN102443638A (en) | Internal reference for detecting miRNA (micro Ribonucleic Acid) in serum/blood plasma and application of internal reference | |
| CN107653319B (en) | Glioma diagnosis marker circ8:61680968|61684188 and application | |
| CN107937538B (en) | Glioma diagnosis marker circ1:201817088|201817285 and application | |
| CN107937528B (en) | Glioma prognosis marker hsa _ circ _0125365 and application | |
| CN107937529B (en) | Glioma diagnosis marker hsa _ circ _0135404 and application | |
| CN109161596B (en) | Application of miR-129 and target gene thereof in detection of lung adenocarcinoma | |
| CN113265466A (en) | Long-chain non-coding RNA and application thereof in diagnosis and treatment of hepatocellular carcinoma | |
| CN107365859B (en) | Molecular markers of the LncRNA as diagnosis and treatment osteosarcoma | |
| CN107937531B (en) | Glioma diagnosis marker circ7:73686636|73687095 and application | |
| CN107604074B (en) | Glioma prognostic marker circ15:101235082|101235577 and application thereof | |
| Sterbova et al. | The use of Human Inflammatory Response and Autoimmunity RT2 lncRNA PCR Array for plasma examination in breast cancer patients prior to therapy | |
| CN107937527B (en) | Glioma diagnosis marker circ1:43920404|43920928 and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200630 |